Stopping dupilumab

Phase 3Monoclonal antibody

UUniversity Hospital, Toulouse

Stopping dupilumab is one of 26 small molecule programs targeting Asthma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaNot yet recruiting

AsthmaPhase 3

Not yet recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Stopping dupilumab

UUniversity Hospital, Toulouse

Phase 3

1 2

Celexa

AbbVie

Preclinical

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

Atrovent

2 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Post-ApprovalNot yet recruiting

Asthma

NCT06818019

Clinical

Trials by Indication[1]

Asthma1 trial

Withdrawal of Dupilumab in Severe Asthma

Not yet recruiting·UUniversity Hospital, Toulouse·Phase 4·NCT06818019·205 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Stopping dupilumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stopping dupilumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stopping dupilumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Toulouse

Stopping dupilumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Asthma1 trial

References

Drug Info

Quick Facts

Related News